17 research outputs found
Recommended from our members
Can You Imagine a Better Academic E-book Experience? Piloting SimplyE in Academic Libraries
SimplyE, an end-user library reading app for ebook and audiobooks developed by the New York Public Library, continues to gain momentum across public and academic libraries. New efforts are underway to better understand the needs of academic ebook readers and advance open-source software to meet the needs of institutions and students. SimplyE and the technologies it uses have evolved and proliferated. User expectations have evolved. With more media types, digital rights management (DRM), and content hosting capabilities it is now closer than ever to becoming an ebook solution for academic libraries. Learn about recent accomplishments, current efforts, and future plans to improve SimplyE and expand its use in academic and public libraries
Strategies for Innovation and Sustainability: Insights from Leaders of Open Source Repository Organizations
4th International Conference on Open RepositoriesThis presentation was part of the session : Conference PresentationsThis panel convenes leaders of organizations that provide the major open repository software platforms featured at OR09. This session provides an opportunity to learn about the strategic processes behind the software - both from a technical and business perspective. The panelists will each provide an overview of their strategic approach open source and open repositories. Specific attention will be paid to strategies for promoting innovation, governance and organization models, and revenue and business models. The area of sustainability and business models for open source software is active and evolving and there is no one-size-fits-all solution. The panelists will discuss their views on ensuring the health and vitality of their platforms, addressing challenges such as: ensuring stability while promoting innovation; generating revenue; enabling community process, governance, and organizational development
Recommended from our members
DPLA Exchange and SimplyE, an open platform for e-content services
This presentation describes a pilot program spearheaded by the Digital Public Library of America (DPLA) to test a new model for a library-owned and library-centered ebook marketplace for popular ebooks, together with free public domain and openly-licensed ebooks. The goal of the program is to demonstrate how DPLA can help libraries maximize access to ebooks for their patrons. For the pilot, DPLA sought out a mix of library types including a state library, a consortium, and both a large public library and one serving smaller and rural populations. The diverse group of pilot libraries are: Alameda County Library (CA); Carnegie Library of Pittsburgh (PA); Connecticut State Library (CT); Califa Library Group (CA, KS); St. Maryâs County Library (MD) and Yavapai Library Network (AZ)
Recommended from our members
It Takes a Village: Open Source Software Sustainability
This Guidebook is designed to serve as a practical reference source to help open source software programs serving cultural and scientific heritage organizations plan for long-term sustainability, ensuring that commitment and resources will be available at levels sufficient for the software to remain viable and effective as long as it is needed.
One of the most significant themes of this Guidebook is that sustainability is not a linear process, with set beginning and end points. Program sustainability shifts and evolves over time across a number of phases and facets. The phases speak to where a program is in its lifecycle: getting started, growing, or stable but not static. The facets describe the different components of sustainability, each of which is critical to overall program health, but may have different timelines, goals, and resource needs. The facets deemed
most critical by the Guidebookâs authors and contributors are: Governance, Technology, Resources (Financial and Human), and Community Engagement.
Sections of the Guidebook will: define the phases and facets of sustainability; identify goals, characteristics, and common roadblocks for each phase in each facet; provide guidance for moving an OSS program to the next phase in a given facet, with the understanding that the same program may be in different phases along different facets of sustainability; and highlight case studies and additional resources to help a programâs research and decision-making process.
The Guidebook is intended for a broad audience. While certain paths may be of more interest than others, we would recommend reading through each of the facets before returning to the one that aligns most closely with a specific role, e.g., governance for a program manager, technology for a technical lead, engagement for a community manager, or resources for an administrator. The worksheet in Appendix A can help identify the specific phase a program is in along each facet.
The open source landscape is wide and varied. Bringing open source programs serving cultural and scientific heritage together under one shared umbrella can provide us all with the power to better advocate for our needs, develop shared sustainability strategies, and provide our communities with the information needed to assess and contribute to the sustainability of the programs they depend on
Recommended from our members
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (nâ=â143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (nâ=â152), or no hydrocortisone (nâ=â108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (nâ=â137), shock-dependent (nâ=â146), and no (nâ=â101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707
Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19
IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19.
Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19.
DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 nonâcritically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022).
INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (nâ=â257), ARB (nâ=â248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; nâ=â10), or no RAS inhibitor (control; nâ=â264) for up to 10 days.
MAIN OUTCOMES AND MEASURES The primary outcome was organ supportâfree days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes.
RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ supportâfree days among critically ill patients was 10 (â1 to 16) in the ACE inhibitor group (nâ=â231), 8 (â1 to 17) in the ARB group (nâ=â217), and 12 (0 to 17) in the control group (nâ=â231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ supportâfree days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively).
CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570
DuraCloud Pilot Program: utilizing cloud infrastructure as an extension of your repository
Cloud compute and cloud storage are now available from several commercial providers around the globe as a commodity service. Due to the extremely low cost, ease of use, and instant scalability the Academic community is taking a hard look at how to best utilize this resource as an extension of its own IT environment. Even though there has been much interest in using cloud infrastructure few organizations have seriously integrated the cloud as part of their environment due to several challenges foreseen, whether real of perceived. In a large survey undertaken by the DuraSpace organization in Winter 2010, some of the biggest challenges identified by our community were security, performance, reliability and trust. Little data has been published to either validate or discredit the key challenges noted within the academic community, although much anecdotal information exists regarding site outages, poor performance, loss of data and the like. The purpose of this presentation is to present the findings of a large scale pilot program utilizing cloud infrastructure from multiple commercial cloud providers, as a utility. The presentation will discuss the key challenges and benefits identified when using cloud storage and compute as a utility during the pilot program. The presentation will provide detailed analysis, where possible, across multiple cloud providers. The analysis presented will include, when applicable, what solutions were deployed to overcome security, reliability, performance and other identified technical issues
DuraCloud Pilot Program: utilizing cloud infrastructure as an extension of your repository
Cloud compute and cloud storage are now available from several commercial providers around the globe as a commodity service. Due to the extremely low cost, ease of use, and instant scalability the Academic community is taking a hard look at how to best utilize this resource as an extension of its own IT environment. Even though there has been much interest in using cloud infrastructure few organizations have seriously integrated the cloud as part of their environment due to several challenges foreseen, whether real of perceived. In a large survey undertaken by the DuraSpace organization in Winter 2010, some of the biggest challenges identified by our community were security, performance, reliability and trust. Little data has been published to either validate or discredit the key challenges noted within the academic community, although much anecdotal information exists regarding site outages, poor performance, loss of data and the like. The purpose of this presentation is to present the findings of a large scale pilot program utilizing cloud infrastructure from multiple commercial cloud providers, as a utility. The presentation will discuss the key challenges and benefits identified when using cloud storage and compute as a utility during the pilot program. The presentation will provide detailed analysis, where possible, across multiple cloud providers. The analysis presented will include, when applicable, what solutions were deployed to overcome security, reliability, performance and other identified technical issues